Acumen Pharmaceuticals (ABOS) risk factors, FY2024 10-K

Risks Related to our Financial Position and Capital Needs

1. 01We are a clinical-stage biopharmaceutical company with a limited operating history
2. 02We have no product candidates approved for commercial sale, we have never generated any revenue from product sales and we may never be profitable
3. 03The terms of our Loan Agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility
4. 04We are exposed to interest rate risk under our Loan Agreement with K2HV, which could cause our debt service obligations to increase significantly

Risks Related to the Development of our Product Candidates

1. 05We have concentrated our research and development efforts on the treatment of AD, a field that has to date seen very limited success in drug development
2. 06Our approach to the potential treatment of AD is based on a novel therapeutic approach, which exposes us to unforeseen risks
3. 07clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain
4. 08Clinical failure can occur at any stage of clinical development, and we have never submitted a biologics license application, or BLA, or other marketing authorization application, or MAA
5. 09We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates
6. 10commercial profile of an approved label or result in significant negative consequences following marketing approval, if any
7. 11We have experienced and may continue to experience delays or difficulties in the enrollment and retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals
8. 12Interim, “topline” and preliminary results from our clinical trials that we announce or publish from time to time may change as more data become available and is subject to audit and verification procedures that could result in material changes in the final data
9. 13We cannot be certain that sabirnetug or any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market our product candidates
10. 14We may in the future conduct clinical trials for our product candidates outside the United States, and the FDA, EMA and other comparable foreign regulatory authorities may not accept data from such trials
11. 15We may not be successful in our efforts to build a pipeline of additional product candidates
12. 16If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed
13. 17We may develop sabirnetug and future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks
14. 18Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
15. 19Due to the recent change in U.S. presidential administration, we face uncertainty regarding potential regulatory developments that may adversely affect our business

Risks Related to the Commercialization of Our Product Candidates

1. 20Even if sabirnetug or any other product candidate we may develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
2. 21The affected populations for sabirnetug or any other product candidate we may develop may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates
3. 22Off-label use or misuse of our products may harm our reputation in the marketplace, result in injuries that lead to costly product liability suits, and subject us to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any product
4. 23We may pursue Breakthrough Therapy designation by the FDA. This designation may not actually lead to a faster development or regulatory review or approval process, and it does not assure FDA approval of any product candidates we may develop
5. 24We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more effective than ours
6. 25Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
7. 26The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these therapies
8. 27Foreign governments also have their own healthcare reimbursement systems, which vary significantly by country and region, and we cannot be sure that coverage and adequate reimbursement will be made available with respect to the treatments in which our products are used under any foreign reimbursement system
9. 28Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
10. 29We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business
11. 30If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could seriously harm our business

Risks Related to Our Dependence on Third Parties

1. 31We currently rely on CMOs to supply components of and manufacture sabirnetug. The loss of any of these CMOs or the failure of any of them to meet their obligations to us could affect our ability to develop sabirnetug in a timely manner
2. 32We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions
3. 33We will likely seek collaborations with third parties for the development and commercialization of sabirnetug or any future product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates, including sabirnetug
4. 34We may be exposed to a variety of international risks that could materially adversely affect our business
5. 35If we engage in acquisitions, we will incur a variety of costs and we may never realize the anticipated benefits of such acquisitions

Risks Related to Our Intellectual Property

1. 36of claims that may be enforced in the patents that may be issued from the applications we may own or license from third parties. Further, if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected
2. 37application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. It remains unclear what impact the America Invents Act will have on the operation of our business
3. 38Patent terms may be inadequate to protect our competitive position on our product candidate for an adequate amount of time
4. 39If we do not obtain patent term extension for our product candidate our business may be materially harmed
5. 40If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
6. 41Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 42Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidate
8. 43We may not be able to protect our intellectual property rights throughout the world
9. 44Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license
10. 45We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
11. 46We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through in-licenses
12. 47Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery and development efforts
13. 48We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers
14. 49Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
15. 50If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected

Risks Related to Legal and Regulatory Compliance Matters

1. 51providers, marketing expenditures or pricing information and/or require licensing or registration of sales representatives
2. 52The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products
3. 53Even if we obtain regulatory approval for sabirnetug or any future product candidates, they will remain subject to ongoing regulatory oversight, which may result in significant additional expense
4. 54In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy
5. 55Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations
6. 56Our business activities may be subject to the U.S. Foreign Corrupt Practices Act of 1977, or FCPA, and similar anti-bribery and anti-corruption laws
7. 57Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could significantly harm our business
8. 58Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity or a natural disaster
9. 59Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities

Risks Related to Employee Matters and Managing our Growth

1. 60We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth
2. 61We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants
3. 62If we fail to build our finance infrastructure and improve our accounting systems and controls, we may be unable to comply with the financial reporting and internal controls requirements for publicly traded companies

Risks Related to Ownership of our Common Stock and our Status as a Public Company

1. 63An active trading market for our common stock may not continue to be developed or sustained
2. 64The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses
3. 65If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
4. 66Future sales of our common stock in the public market could cause our share price to fall
5. 67Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result
6. 68Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions
7. 69We are an “emerging growth company” and a “smaller reporting company” and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors
8. 70Our management team may use our cash and cash equivalents, including the net proceeds from our initial public offering, in ways in which you may not agree or in ways which may not yield a return
9. 71We have never paid dividends on our capital stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases
10. 72Our failure to meet Nasdaq’s continued listing requirements could result in a delisting of our common stock
11. 73Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
12. 74We incur significant costs and demands upon management as a result of being a public company
13. 75interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies
14. 76Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
15. 77Changes in U.S. tax law could adversely affect our financial condition and results of operations
16. 78Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations